home / stock / rttr / rttr news

RTTR News and Press, Ritter Pharmaceuticals From 03/29/19

Stock Information
Company Name: Ritter Pharmaceuticals
Stock Symbol: RTTR
Market: NASDAQ
Menu
RTTR RTTR Quote RTTR Short RTTR News RTTR Articles RTTR Message Board
Get RTTR Alerts

News, Short Squeeze, Breakout and More Instantly...
RTTR - Ritter Pharmaceuticals misses by $0.86

Ritter Pharmaceuticals (NASDAQ: RTTR ): FY GAAP EPS of -$3.66 misses by $0.86. More news on: Ritter Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

RTTR - Ritter Pharmaceuticals Reports Year End 2018 Financial Results and Provides Business Update

LOS ANGELES, March 29, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointestinal disease...

RTTR - INO, MBT and IGC among premarket gainers

SPI Energy (NASDAQ: SPI ) +115%  on completing its previously announced second-stage acquisition of 100% of the equity interest of HELIOHRISI S.A. More news on: SPI Energy Co., Ltd., One Stop Systems, Inc., Superconductor Technologies Inc., Stocks on the move, Read more ...

RTTR - KIRK and FRSX among premarket losers

Kopin (NASDAQ: KOPN )  -24%  on secondary offering . More news on: Kopin Corporation, PHI, Inc., Yield10 Bioscience, Inc., Stocks on the move, Read more ...

RTTR - Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Top-line Data Readout Expected in early Q4 2019 LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut micro...

RTTR - Dr. William Chey Highlights Unmet Medical Need of Lactose Intolerance and Potential for Phase 3 Drug Candidate RP-G28 in Expert Call Hosted by Ritter Pharmaceuticals

LOS ANGELES, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an...

RTTR - Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019

Leading Gastrointestinal Disease Expert to Address Unmet Medical Need in Lactose Intolerance and the Potential of Phase 3 Drug Candidate RP-G28 LOS ANGELES, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the &#x...
RTTR - Ritter Pharmaceuticals To Present at Noble Capital Markets' Fifteenth Annual Investor/Equity Conference on January 28, 2019

LOS ANGELES, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an ini...

RTTR - Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial  for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019 LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceutica...

RTTR - Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

LOS ANGELES, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an init...
Previous 10 Next 10